Drug intelligence / Profile preview

QR01019

Development stage: Unknown
Lead developer: Wuhan Langlai Technology Development
Modality: Small Molecules
Administration: Oral

Overview

QR01019 is a small molecule antihypertensive agent being developed by Wuhan Langlai Technology Development Co., Ltd. for the treatment of primary hypertension. It is a potassium salt formulation designed to be bioequivalent to azilsartan kamedoxomil (brand name Edarbi). As an angiotensin II receptor blocker (ARB), it selectively binds to the AT1 receptor, inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II, thereby lowering blood pressure. Clinical development has included open-label, randomized crossover bioequivalence trials in healthy adults to evaluate its pharmacokinetics, food effect, and safety profile compared to the reference drug azilsartan kamedoxomil.

Targets

AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on QR01019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QR01019.

Explore the full profile